<DOC>
	<DOCNO>NCT01915732</DOCNO>
	<brief_summary>This multicentre , randomize , assessor-blind , comparator-controlled evaluation efficacy , safety , tolerability Duac™Once Daily Gel clindamycin phosphate gel topical treatment mild moderate facial acne vulgaris . A total 1020 subject enrol , 510 per study arm . The subject males female 12 45 year age , inclusive , time consent , mild moderate facial acne vulgaris . Subjects use Duac™Once Daily Gel ( daily evening ) clindamycin phosphate gel twice daily ( morning evening ) 12 week . The subject evaluate change lesion count , investigator 's static global assessment ( ISGA ) , subject 's global assessment ( SGA ) , local tolerability AEs/SAEs Weeks0 , 1 , 2 , 4 , 8 , 12 ( early withdrawal ) . In addition , quality life measure perform every study visit .</brief_summary>
	<brief_title>A Efficacy Safety Duac™Compared With Clindamycin Phosphate Gel Treatment Mild Moderate Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>1 . Male female subject 12 45 year age , inclusive age calculate date birth , 0 birth . 2 . Subjects : . A minimum 17 60 facial inflammatory lesion ( papule plus pustule ) , 1 facial nodular lesion , NO cystic lesion . ii . A minimum 20 125 facial noninflammatory lesion ( open close comedo ) . 3 . Subjects ISGA score 2 3 Baseline . 4 . Subjects 18 year age old must provide write informed consent ( accord local national authorization requirement ) . Subjects legal age consent must provide assent write informed consent subject parent legal guardian ( accord local national authorization requirement ) . 5 . Subjects willing able complete study , understand comply requirement study , abide restriction , apply medication instruct , return require study visit . 6 . Subjects good health free clinically significant disease , acne vulgaris , might interfere study evaluation . 7 . Female subject childbearing potential must negative pregnancy test baseline . Sexually active female childbearing potential participating study must use medically acceptable method contraception least 6 consecutive month prior start study treatment , must use medically acceptable method contraception receive protocolassigned product . A woman childbearing potential define one biologically capable become pregnant ; include perimenopausal woman le 2 year last menses . Medically acceptable contraceptive method include follow : Hormonal contraception , include oral , injectable , implantable method start least 6 month prior screen . Reliable barrier method include condom diaphragms . A cervical cap also reliable barrier method , provide female subject never give birth naturally . The combined use condom spermicide constitute 2 form acceptable nonhormonal contraception , provide use properly . The use spermicide alone improper use condom inferior method contraception . Subjects surgical sterilization , include tubal ligation partner 's vasectomy , must use form nonhormonal contraception . A barrier method sterilization plus spermatocide acceptable . Females currently sexually active must agree use medically accept method contraception become sexually active participate study . Subjects treat estrogen , androgen , antiandrogenic agent use prevention pregnancy ( control acne ) least 6 consecutive month prior first dose investigational product may enrol long expect change dose , drug , discontinue use study . 1 . Female subject pregnant , try become pregnant , lactate . 2 . Subjects cystic acne lesion , acne conglobata , acne fulminans , secondary acne ( e.g . chloracne druginduced acne ) . 3 . Subjects clinically relevant find baseline physical examination medical history severe systemic disease diseases facial skin acne vulgaris . 4 . Subjects facial hair may prevent accurate assessment acne vulgaris grade lesion count . 5 . Subjects history presence regional enteritis inflammatory bowel disease ( e.g . ulcerative colitis , pseudomembranous colitis , chronic diarrhoea , history antibioticassociated colitis , bloody diarrhoea ) similar symptom . 6 . Subjects use prohibited medication , undergone prohibited procedure treatment within require washout period . 7 . Subjects know hypersensitivity previous allergic reaction active component , lincomycin , excipients investigational product . 8 . Subjects employee clinical research organization involve study , Stiefel , GSK immediate family member ( partner , offspring , parent , sibling , sibling 's offspring ) employee , investigator , his/her study staff . 9 . Subjects member household study time . 10 . Subjects use traditional remedy know affect acne vulgaris within last 4 week . 11 . Subjects major illness within 30 day study enrolment . 12 . Subjects condition judgement investigator would put subject unacceptable risk participation study . 13 . Subjects participate clinical trial take investigate drug within 4 week study enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>